CAMP4 THERAPEUTICS CORP (CAMP) Fundamental Analysis & Valuation
NASDAQ:CAMP • US13463J1016
Current stock price
5 USD
-0.16 (-3.1%)
At close:
5.002 USD
+0 (+0.04%)
After Hours:
This CAMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CAMP Profitability Analysis
1.1 Basic Checks
- In the past year CAMP has reported negative net income.
- In the past year CAMP has reported a negative cash flow from operations.
- In the past 5 years CAMP always reported negative net income.
- In the past 5 years CAMP reported 4 times negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -61.48%, CAMP is in line with its industry, outperforming 40.62% of the companies in the same industry.
- CAMP's Return On Equity of -90.54% is in line compared to the rest of the industry. CAMP outperforms 47.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.48% | ||
| ROE | -90.54% | ||
| ROIC | N/A |
ROA(3y)-66.31%
ROA(5y)-45.58%
ROE(3y)-87.52%
ROE(5y)-75.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CAMP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CAMP Health Analysis
2.1 Basic Checks
- CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CAMP has more shares outstanding
- Compared to 5 years ago, CAMP has more shares outstanding
- CAMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of 0.69, we must say that CAMP is in the distress zone and has some risk of bankruptcy.
- CAMP's Altman-Z score of 0.69 is fine compared to the rest of the industry. CAMP outperforms 61.32% of its industry peers.
- A Debt/Equity ratio of 0.00 indicates that CAMP is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.00, CAMP perfoms like the industry average, outperforming 51.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.69 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
- A Current Ratio of 9.83 indicates that CAMP has no problem at all paying its short term obligations.
- CAMP's Current ratio of 9.83 is fine compared to the rest of the industry. CAMP outperforms 79.30% of its industry peers.
- CAMP has a Quick Ratio of 9.83. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 9.83, CAMP is doing good in the industry, outperforming 79.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.83 | ||
| Quick Ratio | 9.83 |
3. CAMP Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 90.19% over the past year.
EPS 1Y (TTM)90.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.63%
3.2 Future
- CAMP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.78% yearly.
- The Revenue is expected to grow by 86.07% on average over the next years. This is a very strong growth
EPS Next Y64.46%
EPS Next 2Y29.38%
EPS Next 3Y19.13%
EPS Next 5Y12.78%
Revenue Next Year-30.92%
Revenue Next 2Y-51.92%
Revenue Next 3Y50.4%
Revenue Next 5Y86.07%
3.3 Evolution
4. CAMP Valuation Analysis
4.1 Price/Earnings Ratio
- CAMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAMP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CAMP's earnings are expected to grow with 19.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.38%
EPS Next 3Y19.13%
5. CAMP Dividend Analysis
5.1 Amount
- CAMP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CAMP Fundamentals: All Metrics, Ratios and Statistics
5
-0.16 (-3.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2026-03-05/amc
Earnings (Next)05-11 2026-05-11
Inst Owners79.59%
Inst Owner Change60.43%
Ins Owners1.32%
Ins Owner Change0%
Market Cap259.60M
Revenue(TTM)N/A
Net Income(TTM)-53.12M
Analysts85
Price Target8.93 (78.6%)
Short Float %1.2%
Short Ratio2.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.59%
Min EPS beat(2)-12.73%
Max EPS beat(2)9.55%
EPS beat(4)2
Avg EPS beat(4)-56.84%
Min EPS beat(4)-237.33%
Max EPS beat(4)13.17%
EPS beat(8)3
Avg EPS beat(8)-285.46%
EPS beat(12)5
Avg EPS beat(12)-206.26%
EPS beat(16)8
Avg EPS beat(16)-154.85%
Revenue beat(2)2
Avg Revenue beat(2)97.25%
Min Revenue beat(2)49.89%
Max Revenue beat(2)144.61%
Revenue beat(4)4
Avg Revenue beat(4)950.01%
Min Revenue beat(4)49.89%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)459.47%
Revenue beat(12)6
Avg Revenue beat(12)305.91%
Revenue beat(16)6
Avg Revenue beat(16)226.06%
PT rev (1m)0%
PT rev (3m)2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)49.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 68.26 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.42 | ||
| P/tB | 4.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.65
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.07
BVpS1.13
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.48% | ||
| ROE | -90.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-66.31%
ROA(5y)-45.58%
ROE(3y)-87.52%
ROE(5y)-75.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 31.95% | ||
| Cap/Sales | 14.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.83 | ||
| Quick Ratio | 9.83 | ||
| Altman-Z | 0.69 |
F-Score4
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)174.95%
Cap/Depr(5y)129.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.61%
EPS Next Y64.46%
EPS Next 2Y29.38%
EPS Next 3Y19.13%
EPS Next 5Y12.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.63%
Revenue Next Year-30.92%
Revenue Next 2Y-51.92%
Revenue Next 3Y50.4%
Revenue Next 5Y86.07%
EBIT growth 1Y3.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.78%
EBIT Next 3Y-11.62%
EBIT Next 5YN/A
FCF growth 1Y-16.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.9%
OCF growth 3YN/A
OCF growth 5YN/A
CAMP4 THERAPEUTICS CORP / CAMP Fundamental Analysis FAQ
What is the fundamental rating for CAMP stock?
ChartMill assigns a fundamental rating of 2 / 10 to CAMP.
What is the valuation status of CAMP4 THERAPEUTICS CORP (CAMP) stock?
ChartMill assigns a valuation rating of 0 / 10 to CAMP4 THERAPEUTICS CORP (CAMP). This can be considered as Overvalued.
Can you provide the profitability details for CAMP4 THERAPEUTICS CORP?
CAMP4 THERAPEUTICS CORP (CAMP) has a profitability rating of 1 / 10.
What is the financial health of CAMP4 THERAPEUTICS CORP (CAMP) stock?
The financial health rating of CAMP4 THERAPEUTICS CORP (CAMP) is 4 / 10.